Navigation Links
Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Date:9/4/2009

CRANBURY, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its fourth quarter and fiscal year 2009 financial results on Tuesday, September 8, 2009, before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 8, 2009, which will include discussion of the results of operations in greater detail and an update on corporate developments.

    Schedule for the Financial Results Press Release, Conference Call/Webcast

    - Q4 & Fiscal Year 2009 Financial Results
       Press Release                                 9/8/2009 at 7:30 a.m. ET

    - Q4 & Fiscal Year 2009 Conference Call-Live     9/8/2009 at 11:00 a.m. ET
      Domestic Dial-In Number                        1-800-776-0816
      International Dial-In Number                   1-913-312-0854
      Passcode                                       1405577

    - Q4 & Fiscal Year 2009 Conference Call-Replay   9/8-9/15/2009
      Domestic Dial-In Number                        1-888-203-1112
      International Dial-In Number                   1-719-457-0820
      Passcode                                       1405577

    - Webcast Live and Replay Access                http://www.palatin.com

      The webcast and replay can be accessed by logging on to the
      "Investor/Media Center-Webcasts" section of Palatin's website at
     http://www.palatin.com

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website athttp://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):